Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Medico Remedies Limited

NSE: MEDICOPharmaceuticalsShort-term ASM stage 1

Share price

₹22.80

+4.44% close of 9 Oct 2026

Market cap ₹194 CrP/E 14.0

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

69

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹194 Cr

P/E ratio

14.0

P/B ratio

2.5

ROCE

23.3%

ROE

18.7%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹54.2452-week low ₹21.53

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 50.0% over the past year, and 10.2% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 5.3% to 7.5% over the last four years.

Whether it grew faster than its sector

It grew 10.2% a year against a sector median of 13.1% — 2.8 percentage points slower.

Room to re-rate, or risk of de-rating

At 14.0× earnings against a market that pays 24.1× across 2199 companies we can price. Its own industry sits at 27.6×, across 4 companies. It is against its own five-year median of 47.7×, the 1st percentile of its own range.

Whether growth justifies the valuation

Priced at 0.6 times its growth rate, on earnings growth of 22%.

Profit growthPrice per ₹1 profitPer 1% growth
Medico Remedies Limited — this one22%/yr14.0×₹0.64
Caplin Point Laboratories Limited19%/yr27.8×₹1.5
Pfizer Limited8%/yr23.8×₹3.0
Cohance Lifesciences Limited-23%/yr155.2×—
Onesource Specialty Pharma Limited24%/yr——
Alivus Life Sciences Limited6%/yr27.5×₹4.6

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 30 of 130 on returns, 71 of 127 on growth, 106 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 23.3% on capital, ahead of 77% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹27 crore of cash from the business, spent ₹19 crore on plant and equipment, and returned ₹10 crore to lenders and shareholders. But only about 45 of every 100 rupees of profit it reported over 10 years arrived as cash — the rest is tied up. Its cash comes back more slowly than it used to: it went from being waiting 52 days for its cash to waiting 84 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 9 checks clear · 78%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 13 Aug 2026 · Standalone · Unaudited

Revenue

₹69 Cr

Revenue vs last year

+81.4%

Revenue vs last quarter

+22.2%

Net profit

₹3 Cr

Profit vs last year

+38.3%

Profit vs last quarter

-57.0%

Net margin

3.6%

EPS

₹0.30

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹194 Cr
Prev close
₹22.80
52w High
₹56.9
52w Low
₹20.5
Enterprise value
₹209 Cr
Beta
0.8
Price CAGR 1y
-56.0%
Price CAGR 3y
-32.0%
Price CAGR 5y
5.0%
Price CAGR 10y
—

Ratios

Return on assets
8.5%
PEG ratio
0.6
P/E ratio
14.0
P/B ratio
2.5
EV / EBITDA
11.9
Industry P/E
37.6
ROCE
23.3%
ROCE 5y average
20.2%
ROE
18.7%
Debt / Equity
0.3
Interest coverage
10.0
Dividend yield
0.0%
ROE 3y average
18.0%
ROE last year
19.0%

Annual P&L

Annual revenue
₹206 Cr
Annual profit
₹13 Cr
Operating margin
8.0%
Net profit margin
6.3%
EBITDA margin
8.3%
Sales growth 3y
13.7%
Sales growth 5y
11.0%
Profit growth 3y
22.0%
Profit growth 5y
38.0%
EPS
₹1.6
Sales growth TTM
50.0%
Profit growth TTM
34.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹69 Cr
Profit latest quarter
₹3 Cr
YoY quarterly sales growth
81.4%
YoY quarterly profit growth
38.5%
OPM latest quarter
4.8%

Balance Sheet

Book Value
₹8.9
Face Value
₹2.0
Total debt
₹19 Cr
Total cash
₹2 Cr
Borrowings
₹19 Cr
Reserves / Equity
3.5

Cash Flow

Operating cash flow
₹6 Cr
Free cash flow
₹1 Cr
FCF yield
-0.2%
Net cash flow
₹1 Cr

Shareholding

Promoter holding
61.4%
FII holding
0.1%
DII holding
0.0%
Public holding
38.5%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,787.0033.94,28,7610.902,901.26.015,299.910.520.5
Divi's Lab.9,548.5085.02,53,4830.31902.065.53,080.027.822.0
Torrent Pharma.4,709.3080.31,79,1270.81566.05.84,921.054.915.2
Zydus Lifesci.1,144.3023.41,14,1440.09990.2-35.18,017.022.021.1
Laurus Labs2,043.70101.01,10,4240.10362.1125.52,026.329.117.8
Cipla1,325.7529.91,07,1030.98785.6-39.27,119.32.315.5
Mankind Pharma2,470.1047.81,02,0260.04574.129.64,030.612.913.5
Medico Remedies22.4513.51860.002.538.569.481.423.3
Median415.1034.72,1640.0713.229.6162.418.615.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Standalone · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales31423041313939413853595769
Expenses29392737283736353550545066
Material Cost292943364047
Change in Inventories-2.61-2.00-4.025.71-1.367.36
Purchases of Stock-in-Trade0.560.621.122.210.461.20
Employee Cost1.581.701.812.131.761.96
Other Expenses5.696.387.668.118.468.38
Operating Profit2.463.072.734.652.822.413.116.662.822.734.337.153.30
OPM %7.827.259.17119.166.127.88167.375.197.38134.76
Other Income0.310.960.270.580.290.681.430.290.661.720.682.871.17
Exceptional items (within Other Income)000000
Interest0.170.180.220.250.180.210.280.490.280.240.390.900.41
Depreciation0.710.710.720.740.750.750.760.770.770.730.790.800.72
Profit before tax1.893.142.064.242.182.133.505.692.433.483.838.323.34
Tax %30233027272725242626253025
Net Profit1.322.431.453.101.581.552.624.341.822.572.875.862.52
EPS in Rs0.160.290.170.370.190.190.320.520.220.310.350.710.30
Diluted EPS in Rs0.520.220.310.350.710.30

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Standalone · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales516754619889122121140145151206238
Expenses486350589586117114131132136189220
Material Cost111149
Change in Inventories-5.16-1.67
Purchases of Stock-in-Trade2.104.41
Employee Cost6.287.40
Other Expenses2131
Operating Profit344333571013151718
OPM %65762.803.204.306791087
Other Income0001221242366
Exceptional items (within Other Income)00
Interest11121111111.161.812
Depreciation1111222232.883.033.093
Profit before tax122222461011141819
Tax %28404352826302628272527
Net Profit1121223578.29101314
EPS in Rs0.250.350.250.150.190.200.310.580.8711.221.581.67
Diluted EPS in Rs1.221.58
Dividend Payout %000000000000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
12%
5 years
11%
3 years
14%
TTM
50%

Compounded profit growth

10 years
28%
5 years
38%
3 years
22%
TTM
34%

Stock price CAGR

10 years
—
5 years
5%
3 years
-32%
1 year
-56%

Return on equity

10 years
14%
5 years
17%
3 years
18%
Last year
19%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital22344441717171717
Reserves121313232426282027364659
Borrowings8141913141415131081419
Other Liabilities141713203532282834364359
Total Liabilities36464859767576778796120153
Fixed Assets87771213151822212120
CWIP003412000003
Investments110000101222
Other Assets2738394863605959647396129
Total Assets36464859767576778796120153

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-3551-116824.895.87
Cash from Investing Activity-3-5-4-3-17-2-7-3-3-5
Cash from Financing Activity6-1-1318-6-2-0-1-1
Net Cash Flow-0-0-00-10-2-0-111
Free Cash Flow-431-2-2832-01.821.58

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days5310712210210998829294125138145
Inventory Days7663961257499587669549072
Days Payable122106112147149143100113108105117119
Cash Conversion Cycle6641058033543954547511198
Working Capital Days2153110884961505254749084
ROCE %101110988101521212123

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Standalone · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters737373737367646361616161
FIIs1.111.290.290.220.220.390.110.070.300.490.030.08
DIIs000.740.970.970.780.010.010.01000
Public262526252532363738383939
No. of Shareholders5,2646,05210,68512,90212,88714,10415,42416,47418,50316,56216,18915,863

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -55.9% (₹51.74 → ₹22.80)Brick size ₹2.30 (fixed)Bricks 35
₹30.00₹40.00₹50.00₹22.80Dec '25Feb '26Apr '26Jun '26Aug '26
Price moved up one brickPrice moved down one brickLast close ₹22.80 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

15.25inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about Medico Remedies Limited. Open one to see why it matters.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Azithromycin API
  • Cephalexin monohydrate API
  • Clarithromycin API
  • Domestic raw materials from Maharashtra manufacturers - FY25 AR: 'Raw materials sourced domestically are easily available from the manufacturers located in Maharashtra'
  • Doxycycline hyclate API
  • Organic antibiotic APIs (HS 294190)
  • Packing materials
  • Penicillins and derivatives (HS 294110)
  • Tetracyclines and derivatives (HS 294130)

Depends on the price of

  • fuel

Buys drug ingredients from

  • Adia (Shanghai) Pharma Co., Ltd., China
  • Shandong Guobang Pharmaceutical Co., China
  • Shinning Pharmaceutical and Chemical, China
  • Zhejiang Chemicals Import and Export Corporation, China
  • Zhejiang Guobang Pharmaceutical Co., China

Sells to

  • Anphar SA de CV · pharmaceutical formulations / medicaments (carried seed edge; no contradiction found)
  • Harleys Ltd · pharmaceutical formulations / medicaments (carried seed edge; no contradiction found)
  • Saad Medical · pharmaceutical formulations / medicaments (carried seed edge; no contradiction found)
  • The Main Pharmacy Association of the Ministry of Health and Medical Industry of Turkmenistan · tablets, capsules and dry syrups (carried seed edge; FY25 AR grounds a 90.2% export mix -…

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE630Y01024

Plants

  • Palghar beta-lactam (penicillin) plant, Plots 15 & 16
  • Palghar formulations complex (three manufacturing units)

News impact

Big market events that reach Medico Remedies Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

16 Mar 2023split₹0

Splits, bonuses & buybacks

  • daily-prices repair: 8 rows from NSE's archive (replace 2, delete 1, insert 5), 2023-11-12..2026-02-01 (docs/flat_day_repair.md)1× · 12 Nov 2023

Bulk & block deals

DateWhoBought / soldSharesPrice
25 Sep 2026SAVITRIBEN MAHENDRAKUMAR SHAHSELL4,37,647₹27.22
4 Aug 2026L7 HITECH PRIVATE LIMITEDBUY4,30,000₹48.32

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.